Symptom measures suggest clinical gains
Participants reported FOCUS easy to use and acceptable
FOCUS was tested in a 30-day single arm trial. N=33 participated.
Participants used FOCUS 86.5% of days they had it, avg. 5x a day.
is usable, acceptable,
and clinically promising
Participants engaged with FOCUS 82% of weeks
FOCUS was deployed as part of a multi-modal relapse prevention program across 8 states.
Participants were at high-risk for relapse. All had a psychotic disorder.
N=342 participated for 6 months.
is engaging to high risk patients
has similar outcomes to clinic-based care
FOCUS was compared in a randomized controlled effectiveness trial with a clinic-based program.
N=163 participated for 3 months.
Engagement was higher and clinical and recovery outcomes were similar.
a mobile health intervention
for people with serious mental illness